- Home
- ADPT vs HCI Comparison
ADPT vs HCI Comparison
Compare ADPT & HCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- HCI
- Stock Information
- Founded
- ADPT 2009
- HCI 2006
- Country
- ADPT United States
- HCI United States
- Employees
- ADPT N/A
- HCI N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- HCI Property-Casualty Insurers
- Sector
- ADPT Health Care
- HCI Finance
- Exchange
- ADPT Nasdaq
- HCI Nasdaq
- Market Cap
- ADPT 1.8B
- HCI 1.7B
- IPO Year
- ADPT 2019
- HCI N/A
- Fundamental
- Price
- ADPT $10.75
- HCI $138.35
- Analyst Decision
- ADPT Strong Buy
- HCI Strong Buy
- Analyst Count
- ADPT 7
- HCI 4
- Target Price
- ADPT $10.57
- HCI $181.25
- AVG Volume (30 Days)
- ADPT 2.1M
- HCI 136.4K
- Earning Date
- ADPT 08-05-2025
- HCI 08-07-2025
- Dividend Yield
- ADPT N/A
- HCI 1.15%
- EPS Growth
- ADPT N/A
- HCI 4.05
- EPS
- ADPT N/A
- HCI 10.46
- Revenue
- ADPT $189,527,000.00
- HCI $759,870,000.00
- Revenue This Year
- ADPT $24.39
- HCI $19.25
- Revenue Next Year
- ADPT $20.44
- HCI $4.08
- P/E Ratio
- ADPT N/A
- HCI $13.29
- Revenue Growth
- ADPT 8.61
- HCI 20.95
- 52 Week Low
- ADPT $3.85
- HCI $87.01
- 52 Week High
- ADPT $12.43
- HCI $176.40
- Technical
- Relative Strength Index (RSI)
- ADPT 48.31
- HCI 32.92
- Support Level
- ADPT $10.22
- HCI $136.75
- Resistance Level
- ADPT $11.18
- HCI $146.77
- Average True Range (ATR)
- ADPT 0.51
- HCI 3.43
- MACD
- ADPT -0.15
- HCI 0.15
- Stochastic Oscillator
- ADPT 24.82
- HCI 15.92
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.